KalVista Pharmaceuticals (KALV) Earning Somewhat Favorable Media Coverage, Report Finds

News coverage about KalVista Pharmaceuticals (NASDAQ:KALV) has been trending somewhat positive on Tuesday, according to Accern Sentiment Analysis. Accern rates the sentiment of news coverage by analyzing more than twenty million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. KalVista Pharmaceuticals earned a news sentiment score of 0.09 on Accern’s scale. Accern also assigned media headlines about the specialty pharmaceutical company an impact score of 45.1080587711855 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the near term.

Shares of KalVista Pharmaceuticals (KALV) opened at $12.78 on Tuesday. KalVista Pharmaceuticals has a twelve month low of $5.48 and a twelve month high of $15.80. The company has a quick ratio of 7.88, a current ratio of 7.88 and a debt-to-equity ratio of 0.01.

KalVista Pharmaceuticals (NASDAQ:KALV) last released its quarterly earnings results on Thursday, September 14th. The specialty pharmaceutical company reported ($0.51) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.59) by $0.08. KalVista Pharmaceuticals had a negative return on equity of 60.42% and a negative net margin of 4,191.47%. The firm had revenue of $0.10 million during the quarter.

A number of research firms recently weighed in on KALV. BTIG Research raised their price target on KalVista Pharmaceuticals from $18.00 to $27.00 and gave the company a “buy” rating in a report on Monday, October 16th. ValuEngine raised KalVista Pharmaceuticals from a “strong sell” rating to a “sell” rating in a report on Wednesday, August 2nd.

WARNING: This piece was posted by The Ledger Gazette and is the property of of The Ledger Gazette. If you are reading this piece on another website, it was illegally copied and republished in violation of US & international copyright laws. The original version of this piece can be read at https://ledgergazette.com/2017/11/14/kalvista-pharmaceuticals-kalv-earning-somewhat-favorable-media-coverage-report-finds.html.

In other news, Director Rajeev M. Shah acquired 850,000 shares of the firm’s stock in a transaction on Thursday, October 12th. The shares were purchased at an average cost of $8.50 per share, for a total transaction of $7,225,000.00. The purchase was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, major shareholder Holdings A/S Novo sold 2,725,283 shares of the stock in a transaction on Thursday, October 12th. The shares were sold at an average price of $9.64, for a total value of $26,271,728.12. The disclosure for this sale can be found here. Insiders sold a total of 2,937,830 shares of company stock worth $27,833,571 over the last quarter. Corporate insiders own 49.10% of the company’s stock.

About KalVista Pharmaceuticals

KalVista Pharmaceuticals, Inc, formerly Carbylan Therapeutics, Inc, is a clinical-stage pharmaceutical company. The Company is focused on the discovery, development, and commercialization of small molecule protease inhibitors for a range of diseases. The Company has developed a portfolio of small molecule plasma kallikrein inhibitors targeting hereditary angioedema (HAE) and diabetic macular edema (DME).

Insider Buying and Selling by Quarter for KalVista Pharmaceuticals (NASDAQ:KALV)

Receive News & Ratings for KalVista Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for KalVista Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply